Probiotics intervention in preventing conversion of impaired glucose tolerance to diabetes: The PPDP follow-on study.

Qun Yan, Weiting Hu, Yan Tian, Xu Li, Yuan Yu, Xing Li, Bo Feng

Journal: Frontiers in endocrinology 2023;14():1113611

PMID: 36875472

Free Full Text on PubMed Central View on PubMed

Plain Language Summary

Compared with normal glucose tolerance, people with prediabetes, especially impaired glucose tolerance (IGT), have a higher risk of developing type 2 diabetes mellitus (T2DM). Early intervention can significantly reduce the probability of developing T2DM in the IGT population. The aim of this study was to observe the effect of early probiotic intervention on the conversion of T2DM after 6 years. This study was a follow-on study of the Probiotics Prevention Diabetes Program (PPDP) Study. A total of 39 non-T2DM patients agreed to continue with the follow up of glucose metabolism for the following 4 years. Results showed that supplementation with active probiotics of Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis is safe, although it does not reduce the risk of IGT conversion to diabetes mellitus. Authors conclude that more clinical and laboratory studies using large samples and long-term observation are needed to explore the effects of different probiotic strains on IGT.

Abstract

OBJECTIVES

The purpose of this study was to assess the incidence of type 2 diabetes mellitus (T2DM) after 6 years in patients with IGT who received early probiotic intervention in the Probiotics Prevention Diabetes Program (PPDP) trial.

METHODS

77 patients with IGT in the PPDP trial were randomized to either probiotic or placebo. After the completion of the trial, 39 non-T2DM patients were invited to follow up glucose metabolism after the next 4 years. The incidence of T2DM in each group was assessed using Kaplan-Meier analysis. The 16S rDNA sequencing technology was used to analyze gut microbiota's structural composition and abundance changes between the groups.

RESULTS

The cumulative incidence of T2DM was 59.1% with probiotic treatment versus 54.5% with placebo within 6 years, there was no significant difference in the risk of developing T2DM between the two groups (=0.674).

CONCLUSIONS

Supplemental probiotic therapy does not reduce the risk of IGT conversion to T2DM.

CLINICAL TRIAL REGISTRATION

https://www.chictr.org.cn/showproj.aspx?proj=5543, identifier ChiCTR-TRC-13004024.

Address: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.; The Second Clinical Medical College, Shanxi Medical University, Second Hospital of Shanxi Medical University, Taiyuan, China.

DOI: 10.3389/fendo.2023.1113611